Melanoma by the State: North Dakota
North Dakota Wants Residents to Protect Their Skin North Dakota is a farming and ranching state, with 39.1 million acres…
Blog - Melanoma360
11/12/2020
Melanoma by the State: North Dakota
North Dakota Wants Residents to Protect Their Skin North Dakota is a farming and ranching state, with 39.1 million acres…
|
11/12/2020
President’s Letter | November 2020
From the Desk of Samantha Guild It’s hard to believe that we’re nearing the holiday season and the end of…
|
11/12/2020
Survivor Spotlight: Stephanie Bowen, Stage IV Survivor
A Woman of Determination By Mara Klecker The second diagnosis came just days before Christmas 2010, almost exactly a decade…
|
11/12/2020
Survivor Spotlight: Tom Lauritzen, Stage III Survivor
On the Road Again…Soon By, Alicia Rowell Tom Lauritzen has lived his whole life in Pittsburgh, Pennsylvania, save for a…
|
11/12/2020
In Plain English—Neo-Adjuvant Therapy for Palpable/Resectable Stage III Melanoma
By Kim Margolin, M.D. In this chapter of “In Plain English,” we will describe the concept of neo-adjuvant therapy. Certain terms…
|
09/29/2020
Have You Checked Out Our New Website?
AIM announced the launch of our redesigned website last week. Have you had an opportunity to take a look? Every…
09/29/2020
President’s Letter |September 2020
From the Desk of Samantha Guild The fall is upon us, and here at AIM at Melanoma, we’re busy with…
|
09/29/2020
Joe Small: Stage III Survivor Spotlight
By, Alicia Rowell It was 2016—October, specifically—when Joe Small showed a little spot on his right forearm to his doctor…
|
09/29/2020
In Plain English: What is a “Triplet,” and Why Does it Matter in Melanoma?
By Kim Margolin, M.D. A “triplet” is the casual term to describe the combination of three drugs to treat cancer.…
|
06/03/2020
President’s Update June | 2020
June|2020 Greetings to the AIM at Melanoma community, Thank you for so many thoughtful acknowledgments and heartfelt tributes for my…
|
Recent Posts
Sep. 05, 2025
Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Sep. 04, 2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
Aug. 26, 2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
Aug. 26, 2025
Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma
Aug. 26, 2025